Dr. Stephen (Steve) Curtis oversees MPM’s investment collaboration with Dana-Farber Cancer Institute and brings to his role experience in early-stage, start-up creation and strategic deal structuring and negotiation in the biotech and pharmaceutical industries. He is also responsible for investment identification, due diligence and business development and supports MPM’s partnership with Gilead Sciences.
Prior to joining MPM, Steve was Senior Director of Business Development – Emerging Technology and Innovation for Eli Lilly and Company, out of Lilly’s external research hub in Cambridge, MA. In that role, he focused on Lilly’s strategic limited partnerships in top-tier venture funds, direct equity investments in selected biotechnology companies, “build-to-buy” investments and other “shared-risk” drug discovery and early development relationships. Prior to Lilly, Steve co-led the Bioscience Ventures group within 2M Companies, the Dallas-based family office of Morton H. Meyerson, focusing on Seed and Series A biotech investments and portfolio management. Before 2M, he worked at Reata Pharmaceuticals, entering through their Biotechnology Leadership Development program and ultimately running the Technology Evaluation and In-Licensing program. Steve also interned at Siemens Venture Capital in Boston while finishing his graduate studies.
Education, Personal, and Fellowship
Steve completed his PhD in biological and biomedical sciences at Harvard Medical School in Boston. His doctoral studies focused on the cellular biology and genetics of lung cancer development, propagation, and progression. Steve graduated summa cum laude from Cornell University, earning a dual BS degree in molecular biology and applied economics and management.
Steve has a personal interest in teaching and enabling students to expand their horizons across disciplines. To that end, he has served as a mentor to graduate students and postdoctoral fellows, giving them the ability to explore venture capital, entrepreneurship, and broader opportunities in the biotech industry. Additionally, Steve serves as an advisor to various incubator/accelerator programs and grant making organizations.
Steve is a member of Class 20, and served the majority of his fellowship at 2M Companies under the mentorship of Melissa Krauth, former Principal of the firm's bioscience ventures group. He completed his fellowship at Eli Lilly & Co as a member of the Emerging Technology and Innovations team, where he focused on shared-risk investment opportunities and the company's LP positions across multiple venture capital funds.